NADAC acquisition cost data for AMITIZA 8 MCG CAPSULE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
| 64764008060 | $5.95 | 2022-02-23 | Rx |
Generic: Lubiprostone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $288.9M | 712,706 | 156,778 | $6.30 |
| 2020 | $279.3M | 660,163 | 141,580 | $6.33 |
| 2021 | $89.4M | 208,506 | 68,150 | $6.31 |
| 2022 | $23.1M | 49,839 | 15,670 | $6.26 |
| 2023 | $8.4M | 18,592 | 5,736 | $6.25 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $978.8K | 2,136 | 496 |
| California | $937.4K | 2,139 | 580 |
| Pennsylvania | $486.6K | 1,188 | 327 |
| Florida | $423.6K | 815 | 305 |
| New Jersey | $408.7K | 711 | 211 |
| North Carolina | $397.3K | 857 | 327 |
| Texas | $379.6K | 821 | 343 |
| Michigan | $321.1K | 682 | 255 |
| Georgia | $305.5K | 641 | 211 |
| Massachusetts | $297.8K | 579 | 151 |
| Missouri | $266.0K | 690 | 188 |
| Ohio | $225.9K | 605 | 182 |
| Connecticut | $217.9K | 381 | 126 |
| Tennessee | $190.1K | 427 | 152 |
| Kentucky | $186.7K | 392 | 156 |
| Illinois | $173.0K | 392 | 121 |
| Louisiana | $169.3K | 442 | 158 |
| Indiana | $164.0K | 378 | 118 |
| Arizona | $131.4K | 279 | 89 |
| Wisconsin | $128.7K | 294 | 108 |
| Virginia | $128.3K | 279 | 88 |
| Maryland | $127.8K | 244 | 83 |
| Alabama | $127.7K | 294 | 103 |
| South Carolina | $107.5K | 206 | 83 |
| Minnesota | $96.9K | 206 | 60 |
| Mississippi | $87.8K | 192 | 71 |
| Oklahoma | $81.9K | 186 | 57 |
| Colorado | $79.6K | 158 | 64 |
| West Virginia | $78.8K | 141 | 51 |
| Kansas | $62.1K | 201 | 51 |
| Arkansas | $59.3K | 163 | 53 |
| Nebraska | $52.1K | 139 | 42 |
| Maine | $49.6K | 98 | 35 |
| Nevada | $48.1K | 87 | 28 |
| Iowa | $47.1K | 122 | 36 |
| Delaware | $47.0K | 71 | 24 |
| Puerto Rico | $33.6K | 92 | 35 |
| New Mexico | $32.4K | 50 | 16 |
| Montana | $31.2K | 99 | 21 |
| Washington | $30.7K | 68 | 24 |
| South Dakota | $28.4K | 79 | 25 |
| Idaho | $25.7K | 65 | 24 |
| Alaska | $23.6K | 101 | 14 |
| North Dakota | $20.1K | 60 | 18 |
| Hawaii | $19.8K | 52 | N/A |
| Rhode Island | $19.8K | 39 | N/A |
| Wyoming | $17.3K | 43 | N/A |
| Oregon | $17.1K | 44 | 17 |
| New Hampshire | $16.1K | 63 | 20 |
| Vermont | $11.6K | 35 | N/A |
| Utah | $8.6K | 33 | 16 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.